Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis

D. Kleinman, A. Douvdevani, Andrew V Schally, J. Levy, Y. Sharoni

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

OBJECTIVE: Our objective was to study the direct action of the gonadotropin-releasing hormone antagonist SB-75 and the agonist buserelin on the proliferation of endometrial cancer cells. STUDY DESIGN: Two human endometrial cell lines that differ in histologic subtype and estrogen receptor content were treated with gonadotropin-releasing hormone analog. We measured the number of viable cells, cell cycle parameters, and apoptotic processes. RESULTS: Growth of the Ishikawa cells was inhibited by SB-75 in a dose-dependent manner. 17β-Estradiol partially abolished the inhibitory effect of SB-75. The growth of the HEC-1A cells was not affected by the antagonist. Neither endometrial cancer cell line showed significant sensitivity to the agonist buserelin. Tenfold concentration of the gonadotropin-releasing hormone agonist did not abolish the inhibitory effect of the antagonist on cell growth. The growth inhibition was not associated with any change in cell cycle parameters but was associated with an induction of apoptosis. CONCLUSION: The gonadotropin-releasing hormone antagonist SB- 75 directly inhibits the growth of some human endometrial cancer cells and thus may be suitable for the treatment of endometrial tumors.

Original languageEnglish
Pages (from-to)96-102
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume170
Issue number1 I
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Hormone Antagonists
Endometrial Neoplasms
Gonadotropin-Releasing Hormone
Apoptosis
Buserelin
Growth
Cell Cycle
Cell Line
Estrogen Receptors
Estradiol
Cell Count
cetrorelix
Neoplasms

Keywords

  • apoptosis
  • cell cycle
  • Endometrial cancer
  • gonadotropin-releasing hormone antagonist

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75 : Role of apoptosis. / Kleinman, D.; Douvdevani, A.; Schally, Andrew V; Levy, J.; Sharoni, Y.

In: American Journal of Obstetrics and Gynecology, Vol. 170, No. 1 I, 01.01.1994, p. 96-102.

Research output: Contribution to journalArticle

@article{499d0df76318488190dc55ea557776f2,
title = "Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis",
abstract = "OBJECTIVE: Our objective was to study the direct action of the gonadotropin-releasing hormone antagonist SB-75 and the agonist buserelin on the proliferation of endometrial cancer cells. STUDY DESIGN: Two human endometrial cell lines that differ in histologic subtype and estrogen receptor content were treated with gonadotropin-releasing hormone analog. We measured the number of viable cells, cell cycle parameters, and apoptotic processes. RESULTS: Growth of the Ishikawa cells was inhibited by SB-75 in a dose-dependent manner. 17β-Estradiol partially abolished the inhibitory effect of SB-75. The growth of the HEC-1A cells was not affected by the antagonist. Neither endometrial cancer cell line showed significant sensitivity to the agonist buserelin. Tenfold concentration of the gonadotropin-releasing hormone agonist did not abolish the inhibitory effect of the antagonist on cell growth. The growth inhibition was not associated with any change in cell cycle parameters but was associated with an induction of apoptosis. CONCLUSION: The gonadotropin-releasing hormone antagonist SB- 75 directly inhibits the growth of some human endometrial cancer cells and thus may be suitable for the treatment of endometrial tumors.",
keywords = "apoptosis, cell cycle, Endometrial cancer, gonadotropin-releasing hormone antagonist",
author = "D. Kleinman and A. Douvdevani and Schally, {Andrew V} and J. Levy and Y. Sharoni",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "170",
pages = "96--102",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1 I",

}

TY - JOUR

T1 - Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75

T2 - Role of apoptosis

AU - Kleinman, D.

AU - Douvdevani, A.

AU - Schally, Andrew V

AU - Levy, J.

AU - Sharoni, Y.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - OBJECTIVE: Our objective was to study the direct action of the gonadotropin-releasing hormone antagonist SB-75 and the agonist buserelin on the proliferation of endometrial cancer cells. STUDY DESIGN: Two human endometrial cell lines that differ in histologic subtype and estrogen receptor content were treated with gonadotropin-releasing hormone analog. We measured the number of viable cells, cell cycle parameters, and apoptotic processes. RESULTS: Growth of the Ishikawa cells was inhibited by SB-75 in a dose-dependent manner. 17β-Estradiol partially abolished the inhibitory effect of SB-75. The growth of the HEC-1A cells was not affected by the antagonist. Neither endometrial cancer cell line showed significant sensitivity to the agonist buserelin. Tenfold concentration of the gonadotropin-releasing hormone agonist did not abolish the inhibitory effect of the antagonist on cell growth. The growth inhibition was not associated with any change in cell cycle parameters but was associated with an induction of apoptosis. CONCLUSION: The gonadotropin-releasing hormone antagonist SB- 75 directly inhibits the growth of some human endometrial cancer cells and thus may be suitable for the treatment of endometrial tumors.

AB - OBJECTIVE: Our objective was to study the direct action of the gonadotropin-releasing hormone antagonist SB-75 and the agonist buserelin on the proliferation of endometrial cancer cells. STUDY DESIGN: Two human endometrial cell lines that differ in histologic subtype and estrogen receptor content were treated with gonadotropin-releasing hormone analog. We measured the number of viable cells, cell cycle parameters, and apoptotic processes. RESULTS: Growth of the Ishikawa cells was inhibited by SB-75 in a dose-dependent manner. 17β-Estradiol partially abolished the inhibitory effect of SB-75. The growth of the HEC-1A cells was not affected by the antagonist. Neither endometrial cancer cell line showed significant sensitivity to the agonist buserelin. Tenfold concentration of the gonadotropin-releasing hormone agonist did not abolish the inhibitory effect of the antagonist on cell growth. The growth inhibition was not associated with any change in cell cycle parameters but was associated with an induction of apoptosis. CONCLUSION: The gonadotropin-releasing hormone antagonist SB- 75 directly inhibits the growth of some human endometrial cancer cells and thus may be suitable for the treatment of endometrial tumors.

KW - apoptosis

KW - cell cycle

KW - Endometrial cancer

KW - gonadotropin-releasing hormone antagonist

UR - http://www.scopus.com/inward/record.url?scp=0028346169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028346169&partnerID=8YFLogxK

M3 - Article

C2 - 8296852

AN - SCOPUS:0028346169

VL - 170

SP - 96

EP - 102

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1 I

ER -